Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.11B P/E - EPS this Y 24.90% Ern Qtrly Grth -
Income -167.48M Forward P/E -5.49 EPS next Y -1.70% 50D Avg Chg 2.00%
Sales 8.19M PEG - EPS past 5Y - 200D Avg Chg -25.00%
Dividend N/A Price/Book 3.13 EPS next 5Y - 52W High Chg -55.00%
Recommedations 1.90 Quick Ratio 3.96 Shares Outstanding 98.31M 52W Low Chg 18.00%
Insider Own 19.60% ROA -42.22% Shares Float 60.10M Beta -1.52
Inst Own 87.02% ROE -45.71% Shares Shorted/Prior 15.10M/13.57M Price 12.80
Gross Margin 91.37% Profit Margin - Avg. Volume 1,224,093 Target Price 39.25
Oper. Margin -1,401.45% Earnings Date - Volume 994,626 Change -4.12%
About Day One Biopharmaceuticals, Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Day One Biopharmaceuticals, Inc News
10/01/24 At What Oil Price Will Shale Drillers Stop Drilling?
08/27/24 Taylor Fritz’s Girlfriend Morgan Riddle Opts for Classic Little Black Dress on Day One of the U.S. Open 2024
08/19/24 Jeff Bezos Said 'I Predict One Day Amazon Will Fail' And Claims Large Companies Only Last '30-Plus Years' – Guess How Old Amazon Is?
08/16/24 A great week that adds to Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) one-year returns, institutional investors who own 56% must be happy
10:46 AM Bank of America Says Buy These 3 Stocks for a Double-Digit Rally
08/07/24 Dow Jones Futures Fuel New Market Rally On Bank Of Japan; Nvidia Partner Super Micro Dives
07/30/24 Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates
07/30/24 Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
07/30/24 Day One Announces Oversubscribed $175.0 Million Private Placement
07/25/24 Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy
06/27/24 Lupita Nyong’o Shimmers in Sequined Off-the-shoulder Prada Jumpsuit and Satin Miniskirt at ‘A Quiet Place: Day One’ Premiere
06/24/24 Lupita Nyong’o Gives Power Suiting a Sensual Spin in Double-breasted Blazer and High-waisted Shorts for ‘A Quiet Place: Day One’ Photo Call
06/22/24 Insider Selling: Director Saira Ramasastry Sells Shares of Day One Biopharmaceuticals Inc (DAWN)
06/19/24 Day One targets the growing ADC market with MabCare acquisition
06/18/24 Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
06/11/24 Exclusive: Day One Ventures closes its third fund at $150 million
05/30/24 Day One Announces Sale of Priority Review Voucher for $108 Million
05/06/24 Day One Reports First Quarter 2024 Financial Results and Corporate Progress
05/04/24 Insider Sale at Day One Biopharmaceuticals Inc (DAWN)
04/23/24 Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
DAWN Chatroom

User Image maikelm82 Posted - 8 hours ago

$DAWN looking good $XBI

User Image Night_Owl_Biotech Posted - 2 days ago

The attachment graphs the share prices of 9 commercial-stage oncology focused biopharmas with market caps of less than $5B since 6/28/24. There's compelling evidence that suggests this pool of bios are the strongest candidate for acquisition (see our 9/23/24 post). These 9 are off 13 to 45% from Q3 2024 peaks. 6 of the 9 are off by more than 20%. This is not investment advice but if you believe investment cycles are cyclical it may be a good time to research this peer group. $URGN closed a $108MM equity financing at $17.50 share not 4 months ago. URGN is off ~25% since. $IOVA $SWTX & $DAWN reported Q2 2024 revenues way ahead of consensus (by at least 15%). IOVA's enterprise value is roughly 6X its FY25 guidance. Investors may also want to pay attention to $DCTH as their CFO said they have enough liquidity to get to profitability.

User Image Ms_P Posted - 4 days ago

$IOVA $GERN $DAWN getting recognition https://www.linkedin.com/posts/califesciences_introducing-the-finalists-for-the-21st-annual-activity-7249206889547247616-qE40?utm_source=share&utm_medium=member_ios

User Image Idvst8 Posted - 4 days ago

$DAWN cheap.

User Image Night_Owl_Biotech Posted - 5 days ago

$SWTX is trading at a year to date low after reporting its second quarterly beat in a row 2 months ago. SWTX shot up after reporting the Q2 2024 beat but is off roughly 28% since (over the last 6-7 weeks). Investors may want to consider SWTX's 2 near-term therapies both of which are anticipated to be Blockbusters (per SWTX's CEO & BofA analysts). We are not qualified to opine on these estimates so we recommend investors research for themselves. Considering Big Pharma's are losing key patents, many believe M&A will eventually pick up. As near as we can tell, SWTX is one of a few high quality targets with meaningful near term revenue pot'l. SWTX trades for ~2.0X FY28 (Year 4) analyst consensus revenue estimates. Centerview Partners' review per IMGN's 14A filing notes median peer Year 4 M&A multiples at 6.0X. SWTX may or may not be a peer. Other comm'l stage oncology focused bios are trading at lows (i.e. $IOVA, $DAWN, $GERN $URGN). This is not investment advice but is it time?

User Image Quantumup Posted - 5 days ago

Needham⬆️the PT on $DAWN to $33 was $32 and reits a Buy rating, after raising its ests for Ojemda based on a short MD survey (N=10)—🔑Takeaways in image: Needham remains confident of Ojemda growing to >$1B in 2030 in 1L/2L PLGG: $eras

User Image anachartanalyst Posted - 5 days ago

$DAWN https://anachart.com/wp-content/uploads/ana_temp/1728468070_soc-img.jpg

User Image Idvst8 Posted - 6 days ago

$DAWN - 1393 watchers. Also, off retail's radar. Good to know. Will go through the 13F's later this week.

User Image Idvst8 Posted - 6 days ago

$DAWN - Low volume. I thought Iovance was anemic. This volume is non-existent. When it comes in, probably moves on AIR. ON radar here.

User Image uberkauft Posted - 1 week ago

$DAWN Day One Biopharmaceuticals, Inc. 14-Day RSI: 47.4 % from 52-Week Low: +42.7% % from 52-Week High: -23.6% Open Interest: 6,553 % Change: +1% Put/Call Ratio: 1.05 % Change: -1.6%

User Image RainbowTrump Posted - 1 week ago

$DAWN I’m the first comment on the day??

User Image TheGunnerAB Posted - 1 week ago

$DAWN @RonIsWrong down on huge volume, what's your take on this one?

User Image Idvst8 Posted - 1 week ago

$DAWN cheap here

User Image RainbowTrump Posted - 1 week ago

$DAWN did they miss sales figures or something???

User Image Rajeshbuffet Posted - 09/28/24

$DAWN $IMCR $IOVA $SWTX $URGN

User Image Night_Owl_Biotech Posted - 09/28/24

The attachment notes the market cap & enterprise value as multiples of FY2026 analyst consensus revenue estimates for all 9 commercial-stage oncology focused biopharmas with market caps from $500MM to $5B. $IOVA & $SWTX trade at the lowest multiple of those with FDA approval within the last year. It's our experience it is 3 years to 85/90% of peak sales for new oncology focused therapies. $URGN closed a $100MM equity offering with accredited investors in mid-June at $17.50 a share after reporting UGN-102 data. URGN filed the NDA last month & now trades for $12.90 (26% lower than the June financing). $IMCR reported $75MM in Q2 2024 product sales ($300MM annualized). IMCR's enterprise value is just over 3X Q2 2024's annualized sales. IMCR has 3 ongoing Phase 3 trials. $DAWN Fierce Pharma provides a great overview of Ojemda's clinical profile v. Novartis' combo & market opportunity. This is not investment advice. More to come.

User Image Doozio Posted - 09/27/24

Chop chop huckleberries as a new 🧠 $dawn is NOW 🧠⏰ in da FUTUre of 🧠⏰♾️

User Image TheGunnerAB Posted - 09/25/24

$DAWN Short Interest is over 15M, the highest I can remember.

User Image Night_Owl_Biotech Posted - 09/20/24

The attachment notes shares prices over the last 13 weeks (3 months) of the XBI & the 7 commercial-stage oncology focused biopharmas with market caps between $1 & $5B. History suggests these are strong candidates for M&A. A table is also provided that shows market cap to enterprise value for all 7 (using 6/30/2024 balance sheet data where cash has likely been burned since). Also provided are current FY2026 analyst consensus revenue estimates sourced via Seeking Alpha. To the far right, FY2026 revenue multiples are provided. $IOVA & $SWTX trade at the lowest multiple of FY2026 revenue estimates (but were also launched sooner than the others excl IMCR). $IMCR recorded $75MM in Q224 revenues ($300MM annualized) & mgmt suggested Kimmtrak still has legs in mUM. This is not investment advice but IOVA's tail looks encouraging as does $DAWN $SNDX FY26 estimates may include contribution from Revumenib that is not approved yet (PDUFA = 12/26/24).

User Image MoneyWise13 Posted - 09/20/24

$DAWN Just going to leave this here

User Image RonIsWrong Posted - 09/20/24

$DAWN alright, since this may be getting some eyeballs.. Here are the highlights from their recent update: - Achieved $8.2 million in OJEMDATM (tovorafenib) net product revenues in initial 2 months of launch - Expanded pipeline with DAY301, potential first-in-class Antibody Drug Conjugate (ADC) targeting PTK7 - Entered into exclusive licensing agreement with Ipsen to commercialize tovorafenib outside of the U.S. for approximately $111 million upfront in cash and equity investment at a premium - Entered into a definitive agreement for an oversubscribed private placement of its securities for total gross proceeds of approximately $175 million The also sold their are pediatric disease Priority Review Voucher for $108M in May. --- Cash Position: The Company’s cash, cash equivalents and short-term investments totaled $361.9 million as of June 30, 2024. see https://ir.dayonebio.com/news-releases/news-release-details/day-one-reports-second-quarter-2024-financial-results-and for the details.

User Image RonIsWrong Posted - 09/20/24

$DAWN getting a little more action now. Look like Martin Shkreli just posted about it on twitter. (hat tip for the Shkreli notice to @WSRX)

User Image Doozio Posted - 4 weeks ago

A new 🧠 $dawn thru $xbi was in June of 2022 not July! Bahhhht anyway a leader of the 🔑? who gives a fook during 🧠⏰♾️

User Image Redposition Posted - 1 month ago

$DAWN Why 🤔

User Image Polip Posted - 1 month ago

$DAWN irrational selling

User Image StockInvest_us Posted - 1 month ago

Signal alert: $DAWN - PivotPoint bottom https://stockinvest.us/l/qEFqG4vynH

User Image shared_alerts Posted - 1 month ago

-09/06/2024- 📉 SCANNER UPDATE📈 $VLRS $DAWN $ARQT $CNK ↩️

User Image DonCorleone77 Posted - 1 month ago

$DAWN This morning from Bank of America's "2H24 Playbook: Catalyst outlook for our SMid biotech coverage"

User Image Night_Owl_Biotech Posted - 1 month ago

We googled "IOVA FY2028 revenue estimates" & got a table by year (attached). For perspective, we took a screenshot of the Centerview Partners written fairness opinion on the Mirati/BMY acquisition where they reviewed 8 M&A transactions, considered peers for Mirati, noting the median year 4 revenue multiple paid was 6.0X. IOVA FY28 revenue estimates = $1.44B so do the math if you believe $IOVA would get a like multiple. Also find a screenshot from Lazard's written fairness opinion on the IMGN/AbbVie transaction. They also reviewed 8 transactions noting the median year 5 multiple paid was 4.0X (mean = 4.2). Notice Lazard notes an $IMGN fair value of up to $20.45/share using year 5 multiples yet IMGN was acquired for $31.45 This is not investment advice. This is for entertainment purposes. We have no idea if IOVA will ever be acquired nor if IOVA would be worth these peer's multiples. Next up will be $DAWN $GERN $SNDX

User Image Bobo1234 Posted - 08/28/24

$DAWN they paid $14.50 for the shares and $14.50 for the pre-funded warrants so they’re not going to sell the stock or exercise the warrants and then sell them for less than $14.50. Does that make sense retards

Analyst Ratings
JP Morgan Overweight Aug 6, 24
HC Wainwright & Co. Buy Aug 1, 24
B of A Securities Buy Aug 1, 24
Needham Buy Jul 31, 24
Needham Buy Jul 30, 24
HC Wainwright & Co. Buy Jul 26, 24
Piper Sandler Overweight Jul 8, 24
HC Wainwright & Co. Buy Jun 20, 24
Needham Buy Jun 19, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Nov 15 Sell 11.69 956 11,176 270,170 11/17/23
Dubow Adam General Counsel General Counsel Nov 15 Sell 11.69 5,313 62,109 11,428 11/17/23
Blackman Samuel C. Head of Research and.. Head of Research and Developme Nov 15 Sell 11.69 709 8,288 1,238,234 11/17/23
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Nov 15 Sell 11.69 3,107 36,321 709,429 11/17/23
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Aug 15 Sell 13.86 922 12,779 267,501 08/17/23
Blackman Samuel C. Head of Research and.. Head of Research and Developme Aug 15 Sell 13.86 668 9,258 1,236,319 08/17/23
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Aug 15 Sell 13.86 2,996 41,525 704,224 08/17/23
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer May 15 Sell 13.12 692 9,079 1,235,592 05/17/23
Bender Jeremy Chief Executive Offi.. Chief Executive Officer May 15 Sell 13.12 3,104 40,724 1,179,484 05/17/23
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Mar 10 Sell 18.0484 10,000 180,484 1,233,660 03/14/23
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Mar 07 Sell 20.0091 12,500 250,114 1,174,276 03/08/23
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Feb 17 Sell 20.0267 9,377 187,790 262,128 02/21/23
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Feb 15 Sell 19.57 674 13,190 1,243,660 02/17/23
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Feb 15 Sell 19.57 3,022 59,141 1,186,776 02/17/23
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Feb 10 Sell 20.0659 10,000 200,659 1,241,710 02/13/23
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Jan 20 Sell 22.7523 10,000 227,523 268,810 01/23/23
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Jan 10 Sell 22.98 10,000 229,800 1,250,148 01/11/23
Grant Julie Papanek Director Director Jan 03 Sell 20.83 25,000 520,750 380,000 01/04/23
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Oct 03 Sell 20.0473 10,000 200,473 304,401 10/05/22
Grant Julie Papanek Director Director Oct 03 Sell 20.03 10,000 200,300 429,358 10/05/22
Grant Julie Papanek Director Director Sep 13 Sell 23.98 245,039 5,876,035 9,418,606 09/15/22
Canaan XI L.P. 10% Owner 10% Owner Sep 13 Sell 23.98 245,039 5,876,035 9,418,606 09/15/22
Grant Papanek Julie Director Director Sep 02 Sell 23.8215 5,000 119,108 439,358 09/15/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Sep 01 Sell 23.48 10,000 234,800 314,401 09/06/22
Grant Papanek Julie Director Director Sep 01 Sell 23.5 5,000 117,500 444,358 09/06/22
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Sep 01 Sell 23.47 10,000 234,700 1,289,338 09/06/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Sep 01 Sell 23.47 12,500 293,375 1,240,375 09/06/22
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Aug 15 Option 0 3,561 1,300,279 08/17/22
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Aug 15 Sell 24.31 941 22,876 1,299,338 08/17/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Aug 15 Option 0 10,686 1,256,878 08/17/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Aug 15 Sell 24.31 4,003 97,313 1,252,875 08/17/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Aug 15 Option 0 4,125 325,490 08/17/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Aug 15 Sell 24.31 1,089 26,474 324,401 08/17/22
Grant Papanek Julie Director Director Aug 04 Sell 20 10,000 200,000 449,358 08/08/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Aug 04 Sell 20.0541 10,000 200,541 321,365 08/05/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Aug 04 Sell 20.0017 12,500 250,021 1,246,192 08/05/22
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Aug 01 Sell 16.881 10,000 168,810 1,296,718 08/03/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Jul 18 Sell 20.00 2,500 50,000 331,365 07/20/22
Grant Papanek Julie Director Director Jul 18 Sell 20.0004 2,600 52,001 459,358 07/20/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Jul 18 Sell 20.0012 2,600 52,003 1,258,692 07/20/22
Grant Papanek Julie Director Director Jul 01 Sell 20 1,800 36,000 463,200 07/12/22
Grant Papanek Julie Director Director Jul 08 Sell 20.00 1,242 24,840 461,958 07/12/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Jul 08 Sell 20.00 1,416 28,320 333,865 07/12/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Jul 08 Sell 20.00 1,795 35,900 1,261,292 07/12/22
York Charles N II COO, CFO and Secreta.. COO, CFO and Secretary Jul 01 Sell 20 2,279 45,580 335,281 07/06/22
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Jul 01 Sell 19.14 10,000 191,400 1,306,718 07/06/22
Bender Jeremy Chief Executive Offi.. Chief Executive Officer Jul 01 Sell 20 2,603 52,060 1,263,087 07/06/22
Atlas Venture Opportunity Fund... 10% Owner 10% Owner Jun 17 Buy 15.00 766,667 11,500,005 766,667 06/22/22
Gladstone Michael Director Director Jun 17 Buy 15.00 766,667 11,500,005 766,667 06/22/22
Blackman Samuel C. Chief Medical Office.. Chief Medical Officer Jun 15 Sell 16.2631 50,000 813,155 1,316,718 06/17/22